The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas

Pituitary

Volumn 17, Issue 3, 2014, Pages 240-245

  Athanasoulia, A P ^a   Sievers, C ^a   Uhr, M ^b   Ising, M ^b   Stalla, G K ^a   Schneider, H J ^c  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b Department of Pharmacokinetics and CSF Analysis ^*  (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

ANKK1 DRD2 Taq1A polymorphism; Dopamine; Prolactinoma; Weight

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; METERGOLINE; PROLACTIN; QUINAGOLIDE; ANKK1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; DRD2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADENOMA; ADULT; ALLELE; ANKK1 GENE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRD2 GENE; FEMALE; GENE; GENOTYPE; HEALTH STATUS; HORMONE SUBSTITUTION; HUMAN; MALE; MICROADENOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RECEPTOR BINDING; RECEPTOR DENSITY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; TREATMENT DURATION; WEIGHT CHANGE; AGED; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PITUITARY NEOPLASMS; WEIGHT REDUCTION; YOUNG ADULT;

ADULT; AGED; ALLELES; ANTINEOPLASTIC AGENTS; BODY MASS INDEX; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; POLYMORPHISM, GENETIC; PROLACTINOMA; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, DOPAMINE D2; WEIGHT LOSS; YOUNG ADULT;

EID: 84905682303     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-013-0496-y     Document Type: Article

References (29)

1. Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 64(4):366-370. doi:10.1111/j.1365-2265.2006.02469.x
2. Schmid C, Goede DL, Hauser RS, Brandle M (2006) Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly 136(15-16):254-258. doi:2006/15/smw-10955
3. Greenman Y, Tordjman K, Stern N (1998) Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 48(5):547-553 (Pubitemid 28252990)
4. Korner J, Lo J, Freda PU, Wardlaw SL (2003) Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia. Obes Res 11(2):311-312
5. Berinder K, Nystrom T, Höybye C, Hall K, Hulting A-L (2011) Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 14(3) 199-207. doi:10.1007/s11102-010-0277-9
6. Silva CMD, Barbosa FRP, Lima GAB, Warszawski L, Fontes R, Domingues RC, Gadelha MR (2011) BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity 19(4):800-805. doi:10.1038/Oby.2010.150
7. Munafo MR, Matheson IJ, Flint J (2007) Association of the DRD2 gene Taq1A polymorphism and alcoholism: a meta-analysis of case-control studies and evidence of publication bias. Mol Psychiatry 12(5):454-461. doi:10.1038/sj.mp. 4001938 (Pubitemid 46652456)
8. Smith L, Watson M, Gates S, Ball D, Foxcroft D (2008) Metaanalysis of the association of the Taq1A polymorphism with the risk of alcohol dependency: a HuGE gene-disease association review. Am J Epidemiol 167(2):125-138. doi:10.1093/aje/kwm281
9. Stice E, Spoor S, Bohon C, Small DM (2008) Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science 322(5900):449-452. doi:10.1126/science.1161550
10. Ritchie T, Noble EP (2003) Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 28(1):73-82 (Pubitemid 36173228)
11. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, Syvalahti EK, Hietala J (1998) The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 3(3):256-260 (Pubitemid 28266335)
12. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(2) 273-288. doi:10.1210/jc.2010-1692
13. Cole TJ, Bellizzi M, Flegal KM, Dietz WH (2000) Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 320(7244):1240-1243 (Pubitemid 30240471)
14. Athanasoulia AP, Sievers C, Ising M, Brockhaus AC, Yassouridis A, Stalla GK, Uhr M (2012) Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur J Endocrinol 167(3) 327-335 doi:10.1530/EJE-12-0198
15. Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla GK, Ghigo E (2007) Hypopituitarism. Lancet 369(9571):1461-1470. doi:10.1016/S0140-6736(07) 60673-4 (Pubitemid 46635784)
16. Cincotta AH, Meier AH (1996) Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 19(6):667-670 (Pubitemid 26182986)
17. Gibson CD, Karmally W, McMahon DJ, Wardlaw SL, Korner J (2012) Randomized pilot study of cabergoline a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes Obes Metab 14(4) 335-340. doi:10.1111/j.1463-1326.2011.01534.x
18. Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C (2013) Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol (Oxf). doi:10.1111/cen.12204
19. Via MA, Chandra H, Araki T, Potenza MV, Skamagas M (2010) Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diabetes Metab Syndr Obes 3:43-48
20. Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V (2002) Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 147(1):77-84 (Pubitemid 34814743)
21. Yermus R, Ezzat S (2002) Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas? Clin Endocrinol (Oxf) 56(4):562 (Pubitemid 34429634)
22. Athanasoulia AP, Ising M, Pfister H, Mantzoros CS, Stalla GK, Sievers C (2012) Distinct dopaminergic personality patterns in patients with prolactinomas: a comparison with nonfunctioning pituitary adenoma patients and age- and gender-matched controls. Neuroendocrinol 96(3):204-211
23. Naliato EC, Violante AH, Caldas D, Lamounier Filho A, Loureiro CR, Fontes R, Schrank Y, Souza RG, Costa PL, Colao A (2007) Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin Endocrinol (Oxf) 67(6):845-852. doi:10.1111/j.1365-2265.2007.02973.x (Pubitemid 350135126)
24. Borcherding DC, Hugo ER, Idelman G, De Silva A, Richtand NW, Loftus J, Ben-Jonathan N (2011) Dopamine receptors in human adipocytes: expression and functions. PLoS One 6(9):e25537. doi:10.1371/journal.pone.0025537
25. Mukherjee R, Yun JW (2013) Bromocriptine inhibits adipogenesis and lipogenesis by agonistic action on alpha2-adrenergic receptor in 3T3-L1 adipocyte cells. Mol Biol Rep 40(5) 3783-3792. doi:10.1007/s11033-012-2455-5
26. Ariza M, Garolera M, Jurado MA, Garcia-Garcia I, Hernan I, Sanchez-Garre C, Vernet-Vernet M, Sender-Palacios MJ, Marques-Iturria I, Pueyo R, Segura B, Narberhaus A (2012) Dopamine genes (DRD2/ANKK1-TaqA1 and DRD4-7R) and executive function: their interaction with obesity. PLoS One 7(7):e41482. doi:10.1371/journal.pone.0041482
27. Huang W, Payne TJ, Ma JZ, Beuten J, Dupont RT, Inohara N, Li MD (2009) Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample. Neuropsychopharmacol 34(2):319-330. doi:10.1038/npp.2008.37
28. Cameron JD, Riou ME, Tesson F, Goldfield GS, Rabasa-Lhoret R, Brochu M, Doucet E (2013) The TaqIA RFLP is associated with attenuated intervention-induced body weight loss and increased carbohydrate intake in post-menopausal obese women. Appetite 60(1):111-116. doi:10.1016/j.appet.2012. 09.010
29. Winkler JK, Woehning A, Schultz JH, Brune M, Beaton N, Challa TD, Minkova S, Roeder E, Nawroth PP, Friederich HC, Wolfrum C, Rudofsky G (2012) TaqIA polymorphism in dopamine D2 receptor gene complicates weight maintenance in younger obese patients. Nutrition 28(10):996-1001. doi:10.1016/j.nut.2011.12.018